BioScrip Reports Second Quarter 2019 Financial Results DENVER, CO

BioScrip Reports Second Quarter 2019

DENVER, CO, July 30, 2019 - BioScrip,

Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and

home care management solutions, today announced its second quarter 2019 financial results.

Second Quarter 2019 BioScrip Highlights

1 Revenue prior to ASC 606

adjustment (bad debt) and contractual adjustments.

Second Quarter 2019 Option Care Highlights

revenue does not reflect the impact of the implementation of ASC 606, which Option Care anticipates will result in the

recognition of amounts historically reported in the provision for doubtful accounts as a reduction to revenue.

Daniel E. Greenleaf, BioScrip's President

and Chief Executive Officer, commented, "In the second quarter of 2019, BioScrip achieved year-over-year gross revenue growth

of 13.1%, while adjusted EBITDA increased 35.4% to $15.5 million. This is the fifth consecutive quarter of sequential, comparable

gross revenue growth for BioScrip, and the operating leverage inherent in our business model is evident in our EBITDA performance.

I am also very pleased that year-to-date gross revenue increased by double-digits at 10.4%. Moreover, this quarter we delivered

on our commitment to improve cash collections, which drove a five-day decrease in net DSO, and lowered bad debt expense as a percentage

of revenue as compared to the first quarter of 2019. Our BioScrip teammates have delivered results better than our expectations

for the first half of 2019. Our pending combination with Option Care, expected to close in early August, will provide an incredible

platform to accelerate growth for BioScrip, as the newly combined company will have a significantly improved capital structure

and a leading market position in the attractive home infusion therapy market."

Financial Guidance and Conference

Given the pending combination with Option

Care, the Company will not be providing BioScrip financial guidance and will not be hosting a quarterly conference call.

ADDITIONAL INFORMATION AND WHERE

On June 26, 2019, BioScrip, Inc. ("BioScrip"

or the "Company") filed with the Securities and Exchange Commission ("SEC") a definitive proxy statement

in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED AND ADVISED TO READ THE PROXY STATEMENT BECAUSE

IT CONTAINS IMPORTANT INFORMATION. The proxy statement and other relevant materials filed by the Company with the SEC may be obtained

free of charge at the SEC's website, at www.sec.gov. In addition, security holders may obtain free copies of the proxy statement

and other relevant materials from the Company by contacting Investor Relations by mail at 1600 Broadway, Suite 700, Denver, CO

80202, Attn: Investor Relations, by telephone at (720) 697-5200, or by going to the Company's Investor Relations page on

its corporate web site at https://investors.bioscrip.com.

PARTICIPANTS IN THE SOLICITATION

The Company and its directors and executive

officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the matters discussed

above. Information about the Company's directors and executive officers is set forth in the proxy statement filed on June

26, 2019. This document can be obtained free of charge from the sources indicated above. Information regarding the ownership of

the Company's directors and executive officers in the Company's securities is included in the Company's SEC filings

on Forms 3, 4, and 5, which can be found through the SEC's website at www.sec.gov. Other information regarding the participants

in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained

in the proxy statement.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent

national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations

across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities

to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy

and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum

of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer

service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Forward-Looking Statements -

This communication, in addition to historical

information, contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995)

regarding, among other things, future events or the future financial performance of BioScrip and Option Care. All statements other

than statements of historical facts are forward-looking statements. In addition, words such as "anticipate," "believe,"

"contemplate," "continue," "could," "estimate," "expect," "intend,"

"may," "plan," "potential," "predict," "project," "seek,"

"should," "target," "will," "would," or the negative of these words, and words

and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking

statements. Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the

benefits of the proposed transaction between BioScrip and Option Care, including future financial and operating results; expected

synergies; BioScrip's and Option Cares plans, objectives, expectations and intentions; the expected timing of completion

of the proposed transaction; and other statements relating to the acquisition that are not historical facts. Forward-looking statements

are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections. Investors

are cautioned that all such forward-looking statements are subject to risks and uncertainties (both known and unknown), and many

factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With

respect to the proposed transaction between BioScrip and Option Care, these factors could include, but are not limited to: the

risk that BioScrip or Option Care may be unable to obtain governmental and regulatory approvals required for the transaction, or

that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could

reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk

that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction,

which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the

risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to

realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative

actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its

subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; and the other risks

contained in BioScrip's most recently filed Annual Report on Form 10-K.

Many of these risks, uncertainties and

assumptions are beyond BioScrip's ability to control or predict. Because of these risks, uncertainties and assumptions, you

should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the

information currently available to the parties on the date they are made, and neither BioScrip nor Option Care undertakes any obligation

to update publicly or revise any forward-looking statements to reflect events or circumstances that may arise after the date of

this communication. Nothing in this communication is intended, or is to be construed, as a profit forecast or to be interpreted

to mean that earnings per BioScrip share for the current or any future financial years or those of the combined company, will necessarily

match or exceed the historical published earnings per BioScrip share, as applicable. Neither BioScrip nor Option Care gives any

assurance (1) that either BioScrip or Option Care will achieve its expectations, or (2) concerning any result or the timing thereof,

in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning

letters, consent decrees, cost reductions, business strategies, earnings or revenue trends or future financial results. All subsequent

written and oral forward-looking statements concerning BioScrip, Option Care, the proposed transaction, the combined company or

other matters and attributable to BioScrip or Option Care or any person acting on their behalf are expressly qualified in their

entirety by the cautionary statements above.

Note Regarding Use of BioScrip Non-GAAP

In addition to reporting financial information

in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP

financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation

or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP,

or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition,

the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other

companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation

and amortization, impairment of goodwill, stock-based compensation expense, and restructuring, integration, pre-merger and other